Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Clinical trial NCT04704934 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04704934
- Sponsor
- Daiichi Sankyo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-21
- Primary completion
- 2026-08-31
- Enrollment
- 490
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.